Sustaining Innovation Analyst Day

IR thematic call on dupilumab

Sanofi and Regeneron hosted a conference call for the financial community focusing on investigational dupilumab following the late breaking data presentation from two trials evaluating dupilumab for inadequately controlled moderate-to-severe atopic dermatitis (SOLO 1 and SOLO 2) at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.

Related press releases